Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments Centre

Blood and bone marrow cancer

Click on the title for more information (where available).

Cooper, K., Kalita, N., Harris, P., Gaisford, W., Shepherd, J. Lenalidomide in combination with dexamethasone for previously untreated multiple myeloma: A Single Technology Appraisal. Southampton Health Technology Assessments Centre (SHTAC), 2017.

Kalita, N; Pickett, K; Lord, J; Frampton, G; Yao, GL; Picot, J. Daratumumab in combination with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma: A Single Technology Appraisal. Southampton Health Technology Assessments Centre (SHTAC) 2018.

Cooper K, Rose M, Harris P, Chorozoglou M, Picot J. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma: A Single Technology Appraisal. Southampton Health Technology Assessments Centre (SHTAC), 2017.

Cooper K, Hartwell D, Copley V, Pickett K, Bryant J. Bortezomib for induction therapy in multiple myeloma before high dose chemotherapy and autologous stem cell transplantation Southampton Health Technology Assessments Centre. 2014.

Cooper K, Picot J, Bryant J, Clegg A. Comparative cost-effectiveness models for the treatment of multiple myeloma. International Journal of Technology Assessment in Health Care 2014; Jan22: 1-8

Cooper K, Bryant J, Colquitt J, Frampton G, Clegg A. Dasatinib, high dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technology Assessment. 2012;16 (23)

Picot J, Cooper K, Bryant J, Clegg A. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Health Technology Assessment 2011;15(41).

Green C, Bryant J, Takeda A, Cooper K, Clegg A, Smith A et al. Bortezomib for the treatment of multiple myeloma patients. Health Technology Assessment 2009;13(1):29-33.

Privacy Settings